Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opening Session Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Opening Session Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies

One Surgery Could Prevent Most Ovarian Cancers

ASTRO Experts Comment on the Results of the SUPREMO Trial

SLNB Alone vs Lymphadenectomy in Cervical Cancer

Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC